Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, 650118, Kunming, China.
The NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, 102206, Beijing, China.
Signal Transduct Target Ther. 2022 Feb 25;7(1):61. doi: 10.1038/s41392-022-00920-4.
Variants are globally emerging very quickly following pandemic prototypic SARS-CoV-2. To evaluate the cross-protection of prototypic SARS-CoV-2 vaccine against its variants, we vaccinated rhesus monkeys with three doses of prototypic SARS-CoV-2 inactivated vaccine, followed by challenging with emerging SARS-CoV-2 variants of concern (VOCs). These vaccinated animals produced neutralizing antibodies against Alpha, Beta, Delta, and Omicron variants, although there were certain declinations of geometric mean titer (GMT) as compared with prototypic SARS-CoV-2. Of note, in vivo this prototypic vaccine not only reduced the viral loads in nasal, throat and anal swabs, pulmonary tissues, but also improved the pathological changes in the lung infected by variants of Alpha, Beta, and Delta. In summary, the prototypic SARS-CoV-2 inactivated vaccine in this study protected against VOCs to certain extension, which is of great significance for prevention and control of COVID-19.
变异株在大流行原型 SARS-CoV-2 之后迅速在全球出现。为了评估原型 SARS-CoV-2 疫苗对其变异株的交叉保护作用，我们用三剂原型 SARS-CoV-2 灭活疫苗对恒河猴进行了疫苗接种，然后用新型 SARS-CoV-2 关注变异株（VOC）进行了攻毒。这些接种疫苗的动物产生了针对 Alpha、Beta、Delta 和 Omicron 变异株的中和抗体，尽管与原型 SARS-CoV-2 相比，几何平均滴度（GMT）有一定程度的下降。值得注意的是，在体内，这种原型疫苗不仅降低了鼻腔、咽喉和肛门拭子、肺部组织中的病毒载量，而且还改善了由 Alpha、Beta 和 Delta 变异株感染的肺部的病理变化。总之，本研究中的原型 SARS-CoV-2 灭活疫苗在一定程度上对 VOC 具有保护作用，这对于 COVID-19 的预防和控制具有重要意义。
